Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoART
2024-518841-12-00Phase 2Suspended
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Feasibility rate. Started Jan 2025; status: suspended.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2024-518841-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518841-12-00.